Cerity Partners LLC Has $14.17 Million Stock Holdings in GSK plc (NYSE:GSK)

Cerity Partners LLC decreased its stake in GSK plc (NYSE:GSK - Free Report) by 3.4% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 419,002 shares of the pharmaceutical company's stock after selling 14,626 shares during the quarter. Cerity Partners LLC's holdings in GSK were worth $14,171,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also recently added to or reduced their stakes in the company. Indiana Trust & Investment Management Co grew its stake in GSK by 200.0% in the fourth quarter. Indiana Trust & Investment Management Co now owns 750 shares of the pharmaceutical company's stock valued at $25,000 after acquiring an additional 500 shares during the period. Crews Bank & Trust acquired a new position in shares of GSK in the 4th quarter valued at approximately $26,000. ST Germain D J Co. Inc. raised its holdings in GSK by 195.5% during the 4th quarter. ST Germain D J Co. Inc. now owns 789 shares of the pharmaceutical company's stock worth $27,000 after buying an additional 522 shares during the period. Sunbelt Securities Inc. boosted its holdings in shares of GSK by 73.8% in the third quarter. Sunbelt Securities Inc. now owns 711 shares of the pharmaceutical company's stock valued at $29,000 after buying an additional 302 shares during the period. Finally, Sierra Ocean LLC bought a new stake in shares of GSK during the fourth quarter worth $32,000. Institutional investors and hedge funds own 15.74% of the company's stock.

Analyst Ratings Changes

GSK has been the subject of a number of research analyst reports. Morgan Stanley started coverage on shares of GSK in a research note on Wednesday, February 12th. They issued an "equal weight" rating for the company. StockNews.com raised GSK from a "buy" rating to a "strong-buy" rating in a research report on Friday, February 7th. Seven research analysts have rated the stock with a hold rating and four have given a strong buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $43.25.

Remove Ads

GSK Stock Up 1.3 %

Shares of GSK stock traded up $0.47 during trading hours on Tuesday, reaching $35.75. 1,906,417 shares of the company's stock were exchanged, compared to its average volume of 4,622,212. The company has a current ratio of 0.78, a quick ratio of 0.52 and a debt-to-equity ratio of 1.12. The company has a 50 day moving average of $37.47 and a two-hundred day moving average of $36.18. The stock has a market cap of $73.75 billion, a P/E ratio of 22.49, a P/E/G ratio of 1.12 and a beta of 0.56. GSK plc has a fifty-two week low of $31.72 and a fifty-two week high of $45.93.

GSK (NYSE:GSK - Get Free Report) last released its quarterly earnings data on Wednesday, February 5th. The pharmaceutical company reported $0.59 EPS for the quarter, beating the consensus estimate of $0.44 by $0.15. GSK had a return on equity of 48.59% and a net margin of 8.13%. On average, sell-side analysts forecast that GSK plc will post 4.14 EPS for the current fiscal year.

GSK Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Thursday, April 10th. Stockholders of record on Friday, February 21st were paid a dividend of $0.3932 per share. The ex-dividend date of this dividend was Friday, February 21st. This is a positive change from GSK's previous quarterly dividend of $0.39. This represents a $1.57 annualized dividend and a dividend yield of 4.40%. GSK's payout ratio is currently 100.63%.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.